^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    casdatifan (AB521)

    i
    Other names: AB521
    Associations

    News

    Trials
    Company:
    Arcus Biosci
    Drug class:
    HIF-2α antagonist
    Related drugs:
    Associations

    News

    Trials
    2ms
    Study of Zanzalintinib (XL092) + AB521 and Zanzalintinib + AB521 + Nivolumab in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Other Advanced Solid Tumors (STELLAR-009) (clinicaltrials.gov)
    P1/2, N=25, Active, not recruiting, Exelixis | Recruiting --> Active, not recruiting | N=140 --> 25
    Enrollment closed • Enrollment change • Metastases
    |
    Opdivo (nivolumab) • casdatifan (AB521) • zanzalintinib (XL092)
    5ms
    ARC-20: A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors (clinicaltrials.gov)
    P1, N=302, Recruiting, Arcus Biosciences, Inc. | N=146 --> 302
    Enrollment change • Combination therapy
    |
    Cabometyx (cabozantinib tablet) • casdatifan (AB521)
    10ms
    Study of Zanzalintinib (XL092) + AB521 and Zanzalintinib + AB521 + Nivolumab in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Other Advanced Solid Tumors (STELLAR-009) (clinicaltrials.gov)
    P1/2, N=140, Recruiting, Exelixis
    New P1/2 trial • Metastases
    |
    Opdivo (nivolumab) • casdatifan (AB521) • zanzalintinib (XL092)
    1year
    ARC-20: A Phase 1 Study of AB521 in Renal Cell Carcinoma and Other Solid Tumors (clinicaltrials.gov)
    P1, N=146, Recruiting, Arcus Biosciences, Inc. | N=86 --> 146
    Enrollment change
    |
    casdatifan (AB521)
    1year
    A Relative Bioavailability Study and Food Effect Study of AB521 in Healthy Adult Volunteers (clinicaltrials.gov)
    P1, N=24, Completed, Arcus Biosciences, Inc. | Recruiting --> Completed
    Trial completion
    |
    casdatifan (AB521)
    over1year
    ARC-20: A phase 1 dose-escalation and dose-expansion study to investigate the safety, tolerability, and pharmacology of HIF-2α inhibitor AB521 monotherapy in patients with clear cell renal cell carcinoma and other solid tumors. (ASCO 2023)
    Exploratory endpoints include changes in expression of erythropoietin and other HIF-2α driven biomarkers in blood and tumor tissues, along with progression-free survival for ccRCC patients during dose expansion. Clinical trial information: NCT05536141.
    Clinical • P1 data • PD(L)-1 Biomarker • IO biomarker
    |
    VHL (von Hippel-Lindau tumor suppressor) • EPAS1 (Endothelial PAS domain protein 1)
    |
    casdatifan (AB521)
    2years
    HIF-2α inhibitor AB521 modulates erythropoietin levels in healthy volunteers following a single oral dose (AACR-NCI-EORTC 2022)
    In this first-in-human study, AB521 demonstrated PK/PD properties that are consistent with a potential best-in-class HIF-2α profile.
    Clinical
    |
    VHL (von Hippel-Lindau tumor suppressor) • EPAS1 (Endothelial PAS domain protein 1)
    |
    casdatifan (AB521)
    over2years
    Abstract 21: AB521 is a Novel and Potent Clinical-stage HIF-2α Inhibitor for the Treatment of Renal Cell Carcinoma (EIKCS 2022)
    No abstract available
    Clinical
    |
    EPAS1 (Endothelial PAS domain protein 1)
    |
    casdatifan (AB521)